[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604442":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":11,"locations":17,"responsibleParty":33,"collaborators":10,"id":36,"slug":10,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":39,"acronym":10,"eligibilityCriteria":40,"healthyVolunteers":41,"sex":42,"minAge":10,"maxAge":10,"enrollmentInfo":43,"targetDuration":10,"studyType":46,"phases":10,"briefSummary":47,"conditions":48,"keywords":51,"overallStatus":20,"whyStopped":10,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},{"fullName":5,"class":6},"Tongji Hospital","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":10},"Metabolic-Associated Fatty Liver Disease patients",null,[12],{"name":13,"role":14,"phone":15,"phoneExt":10,"email":16},"Zhen Li","CONTACT","02783663543","zhenli@hust.edu.cn",[18],{"facility":19,"status":20,"city":21,"state":22,"zip":10,"country":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":30},"Tongji hospital","RECRUITING","Wuhan","Hubei","China",{"type":25,"coordinates":26},"Point",[27,28],114.26667,30.58333,{"lat":28,"lon":27},[31],{"name":13,"role":14,"phone":32,"phoneExt":10,"email":16},"+862783663543",{"type":34,"investigatorFullName":13,"investigatorTitle":35,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Professor","100604442",false,"NCT07149571","To Explore the Value of New MR Technology in Non-invasive Quantitative Assessment of Systemic Metabolism, Disease Status and Prognosis in Patients With Metabolic-Associated Fatty Liver Disease","Inclusion Criteria:\n\n1. Patients with MR examination are clinically suspected or diagnosed with metabolism-related fatty liver disease;\n2. Age\u002Fgender: unlimited;\n3. Patients who voluntarily participate in clinical trials and sign written subject informed consent\n\nExclusion Criteria:\n\n1. Clinical suspicion or diagnosis of metabolism-related fatty liver disease and having been prescribed an MR examination;\n2. Voluntarily participation in the study and provision of written informed consent.",true,"ALL",{"count":44,"type":45},500,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to explore the value of new MR technology in assessing the systemic metabolism, disease status, and prognostic risk of metabolism-related fatty liver disease. By obtaining clinical, imaging, laboratory examination and pathological data of metabolism-related fatty liver disease, image processing software is used to analyze the images, explore the relationship between imaging parameters, body composition and metabolic diseases and metabolism-related fatty liver disease, and achieve non-invasive diagnosis, efficacy evaluation, and prognosis prediction of metabolism-related fatty liver disease. Thereby guiding clinical treatment and improving the prognosis and quality of life of patients with metabolism-related fatty liver disease",[49,50],"Nonalcoholic Fatty Liver Disease","Metabolic-associated Fatty Liver Disease",[52],"MRI, metabolism-related fatty liver disease","2025-08-29",{"date":55,"type":56},"2025-09-02","ACTUAL",{"date":58,"type":56},"2025-04-01",{"date":60,"type":45},"2032-12-31",{"name":5,"class":6},1]